Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calusterone
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Calusterone is a synthetic orally active anabolic-androgenic steroid (AAS) classified as a 17-alkylated androgenic steroid. It is structurally similar to testosterone and bolasterone (its 7α-isomer). Calusterone acts primarily by activating the androgen receptor and can also be converted to estradiol, thereby activating certain estrogen receptors. Its main clinical use has been as an antineoplastic agent in the treatment of metastatic breast cancer in postmenopausal women. The drug may alter estradiol metabolism and reduce estrogen production, contributing to its antitumor effects[1][2][3][4][5][6].
- Brand names
- MethosarbRiedemil
- Other names
- 7β,17α-dimethyltestosteronecalusterone
02
Targets
AR (Adrenergic receptors)ER (Estrogen receptor)
Beyond the preview
Go deeper on calusterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calusterone.